“Our expectations have declined primarily due to ongoing weak customer demand in a large number of industries, continuing inventory-reduction measures by customers and the lower year-over-year prices for many of our products,” said Christian Hartel, President and CEO of WACKER. “Numerous market experts anticipated stronger demand in the second half-year – an assumption that was reflected in our previous forecast.” However, WACKER, like so many other chemical companies, has yet to see a recovery.

Changes to the forecast for 2023 are mainly driven by performance at the WACKER SILICONES and WACKER POLYSILICON business divisions.

According to preliminary figures, sales at WACKER SILICONES came in at €700 million, down by 25 percent year over year. Second-quarter EBITDA is expected to amount to €50 million (previous year: €277 million). WACKER expects full-year sales for the division to come in between €2.7 billion and 2.9 billion (previous guidance: between €3.1 billion and €3.3 billion). The EBITDA margin is projected to be around 10 percent (previous guidance: approximately 15 percent).

Based on preliminary figures, WACKER POLYMERS generated sales of €415 million in the second quarter, down 25 percent compared with the same period last year. EBITDA is anticipated to come in at €75 million, down 17 percent year over year. WACKER now projects full-year sales for the division to range between €1.6 billion and €1.7 billion (previous guidance: €1.8 billion). The EBITDA margin is expected to be approximately 17 percent (previous guidance: slightly above the prior-year level).

According to preliminary figures, WACKER POLYSILICON achieved sales of €515 million during the second quarter. Although sales declined by 10 percent year over year, growth of 16 percent was registered compared with the first quarter. Second-quarter EBITDA is expected to amount to €155 million (previous year: €214 million). WACKER expects full-year sales for the division to range between €1.6 billion and €1.7 billion (previous guidance: between €1.6 billion and €1.8 billion). EBITDA is likely to come in between €300 million and €400 million (previous guidance: between €300 million and €500 million).

Based on preliminary figures, WACKER BIOSOLUTIONS generated sales in the amount of €90 million during the second quarter, a slight increase year over year. EBITDA is likely to come in at €0.5 million (previous year: €8.1 million). WACKER now expects full-year sales for the division to grow by high-single-digit percentage (previous gui-dance: sales growth by low-double-digit percentage). EBITDA is pro-jected to be below the prior-year level (previous guidance: significantly higher than last year).

WACKER will publish its interim report for the first half of 2023 on July 27, 2023.